Corvus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. 

CEO
Richard A. Miller
CEORichard A. Miller
Employees
31
Employees31
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2014
Founded2014
Employees
31
Employees31

CRVS Key Statistics

Market cap
329.28M
Market cap329.28M
Price-Earnings ratio
-4.32
Price-Earnings ratio-4.32
Dividend yield
Dividend yield
Average volume
440.61K
Average volume440.61K
High today
$4.43
High today$4.43
Low today
$4.21
Low today$4.21
Open price
$4.29
Open price$4.29
Volume
441.97K
Volume441.97K
52 Week high
$10.00
52 Week high$10.00
52 Week low
$2.10
52 Week low$2.10

CRVS News

Simply Wall St 4d
Corvus Pharmaceuticals Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus Pharmaceuticals ( ) stock is up 118% in the last year...

Corvus Pharmaceuticals Is In A Good Position To Deliver On Growth Plans

Analyst ratings

100%

of 6 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.